# US 2015/0177245 A1 · Method for Prognosing Response to Cancer Therapy with 5, 10, 15, 20-Tetrakis (Carboxyphenyl) Porphine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0177245 A1
- Document ID: US20150177245A1
- Status: Published application
- Kind: A1
- Application number: 14/643,194
- Filed: 2015-03-10
- Published: 2015-06-25
- Earliest claimed: 2000-11-17
- Assignees: bioAffinity Technologies, Inc.
- Applicants: bioAffinity Technologies, Inc.
- Inventors: Jeffrey Garwin
- Web page: https://patentgrep.com/patent/US20150177245A1

## CPC

- G01N 33/575: for cancer
- A61K 31/409: having four such rings, e.g. porphine derivatives, bilirubin, biliverdine (hemin, hematin A61K31/555)
- G01N 33/5091: {for testing the pathological state of an organism}
- G01N 33/52: Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper {and including single- and multilayer analytical elements (immunological elements G01N33/54386; involving labelled immunochemicals G01N33/58; for haemoglobin or occult blood G01N33/72)}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Presented is a method of prognosing a patient's response to a cancer therapy wherein prior to the therapy contacting a sample of cells from the patient's tissue or organ being treated for the cancer with a solution of TCPP to permit binding of the TCPP to components of the abnormal dysplastic or carcinomic cells, if any are present; detecting TCPP fluorescence in the sample, the presence of TCPP fluorescence being indicative that the sample contains dysplastic or carcinomic cells; at intervals during the therapy and subsequent to the therapy performing steps a-c on another sample of cells from the patient's tissue or organ being treated for the cancer; and determining if the percentage of abnormal pre-cancerous cells in the samples tested during and subsequent to the therapy are reduced as compared with the sample tested prior to the therapy, the reduction being prognostic of the patients response to the cancer therapy.

## Claims

### Claim 1

A kit for detection of dysplastic of carcinomic cells in a sample, the kit comprising TCPP in a container and instructions for its use for detecting of abnormal precancerous or cancerous cells in a sample.

### Claim 2 (depends on 1)

The kit of claim 1, further comprising one or more of:
a) components for collecting the sample of cells;
b) components for adhering the sample to a solid support;
c) control cell samples of known cancerous, dysplastic, metaplastic or normal condition; and
d) components for quantitating TCPP fluorescence.
